Diiodothyropropionic acid: WO2008106213.
The patent application WO2008106213 describes the beneficial effects of thyroid hormone analogue 3,5 diiodothyropropionic acid (DITPA) such as stimulating weight loss in overweight mammals, lowering of triglyceride and treating metabolic syndrome in humans. The human population of the patients selected in the studies mentioned has a body mass index > 25. Two examples of the human clinical studies employing DITPA have been mentioned, namely, the body weight reduction and improvement in metabolic abnormalities in obese adults.
Raval
Saurin
S
Zydus Research Centre, Department of Medicinal Chemistry, Moraiya, Ahmedabad, India. saurinraval@zyduscadila.com
D000328:Adult; D000818:Animals; D002986:Clinical Trials as Topic; D004104:Diiodothyronines / Q000494:pharmacology*; D006801:Humans; D024821:Metabolic Syndrome / Q000188:drug therapy; D009765:Obesity / Q000188:drug therapy*; D050177:Overweight / Q000188:drug therapy; D010330:Patents as Topic; D011422:Propionates / Q000494:pharmacology*; D013963:Thyroid Hormones / Q000494:pharmacology*; D014280:Triglycerides / Q000378:metabolism; D015431:Weight Loss / Q000187:drug effects
D004104:Diiodothyronines; D011422:Propionates; D013963:Thyroid Hormones; D014280:Triglycerides; C082182:3,5-diiodothyropropionic acid